India Pharma Outlook Team | Thursday, 26 February 2026
Zydus Lifesciences is set to launch its Zydus semaglutide generic in India on the very first day the patent expires, a move expected to make the drug more accessible to patients.
The company has received approval from the Drug Controller General of India to manufacture and market semaglutide for type-2 diabetes and obesity, setting the stage for a March 2026 debut.
The Zydus semaglutide generic will be available in 15?mg strength under the brand names Semaglyn, Mashema, and Altreme. It comes with a reusable adjustable pen, allowing patients to dial different doses from a single pen using multiple cartridges. This innovative delivery system aims to cut both cost and packaging waste, offering a more convenient option compared to traditional single-use pens.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
Semaglutide has become a highly prescribed therapy globally for controlling blood sugar and promoting weight loss. However, high prices have limited patient access. Industry experts expect that the launch of generics like Semaglyn, Mashema, and Altreme will significantly lower treatment costs, making it more affordable for a larger population in India.
Competition is heating up as other Indian pharmaceutical companies prepare their own generic versions around the same time. Zydus’ strategy of combining early market entry with a reusable pen sets it apart, promising both affordability and convenience for patients.
By launching Zydus semaglutide generics on day one with advanced delivery, the company is aiming to reshape the Indian diabetes and obesity treatment landscape.
